SLC31A2 and neoplasm: After knockdown of the 50% gene of CTR2 mRNA, the sensitivity of tumor cells to cisplatin increased 2.6- to 2.9-fold, and overexpression of CTR2 increased cisplatin resistance of tumor cells 2.5-fold.